NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 281
(Total Views: 207)
Posted On: 02/05/2020 6:37:28 PM
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Launches Innovative Culture Media for Growing Ovarian Tumor Cells in the Lab
Predictive Oncology (NASDAQ: POAI), together with its subsidiary, TumorGenesis, Inc., today announced that it has selected US Biological Corporation of Salem, Massachusetts as the manufacturer and distributor of its innovative culture media for growing ovarian tumor cells. TumorGenesis media are specially formulated to help researchers isolate and maintain the unique histological and basic biological signatures of heterogeneous ovarian cell types while growing them in the laboratory, unlike traditional cell culture media that select for one or two fast growing cell types. “Using these proprietary media our partners have identified 25 cell types from ovarian tumors, which to a large degree have never been screened or studied by researchers,” TumorGenesis, Inc. President Richard Gabriel said in the news release. “The resulting cells have a 95+% match to cells found in patient bodies.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), together with its subsidiary, TumorGenesis, Inc., today announced that it has selected US Biological Corporation of Salem, Massachusetts as the manufacturer and distributor of its innovative culture media for growing ovarian tumor cells. TumorGenesis media are specially formulated to help researchers isolate and maintain the unique histological and basic biological signatures of heterogeneous ovarian cell types while growing them in the laboratory, unlike traditional cell culture media that select for one or two fast growing cell types. “Using these proprietary media our partners have identified 25 cell types from ovarian tumors, which to a large degree have never been screened or studied by researchers,” TumorGenesis, Inc. President Richard Gabriel said in the news release. “The resulting cells have a 95+% match to cells found in patient bodies.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)